For the quarter ending 2026-03-31, IGC had -$693K decrease in cash & cash equivalents over the period. -$1,224K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,402 | -726 | -1,821 | -1,599 |
| Depreciation and amortization | 58 | 64 | 119 | 141 |
| Provision for bad debt | - | 0 | - | - |
| Impairment of assets | 0 | 0 | - | - |
| Common stock-based compensation and expenses, net | 1,009 | 926 | 730 | 452 |
| Other items | 20 | -2,155 | -1,055 | -24 |
| Accounts receivable, net | 24 | -29 | -46 | 53 |
| Inventory | 0 | -19 | -6 | -11 |
| Deposits and advances | 37 | 25 | -37 | -183 |
| Claims and advances | -10 | -3 | -8 | 0 |
| Accounts payable | 241 | 384 | -303 | 51 |
| Accrued and other liabilities | -98 | 258 | 93 | -599 |
| Operating lease asset | -2 | -2 | -53 | -32 |
| Operating lease liability | -2 | -2 | -3 | -2 |
| Net cash used in operating activities | -1,223 | -1,223 | -2,090 | -1,407 |
| Purchase of property, plant, and equipment | 1 | 12 | 29 | 8 |
| Sale of property, plant, and equipment | 0 | 2 | -23 | 702 |
| Investment in short-term investment | - | - | 25 | - |
| Investment in short-term investments | - | 50 | - | - |
| Acquisition and development of intangible assets | 169 | 193 | 297 | 114 |
| Net cash used in investing activities | -170 | -228 | -374 | 580 |
| Repayment of a long-term loan | - | - | - | -1 |
| Net proceeds from the issuance of common stock | -3,876 | - | 3,111 | 852 |
| Proceeds from common stock subscribed | - | 5,228 | - | - |
| Repayment of long-term loan | - | 1 | 2 | - |
| Net proceeds from the loan | 623 | - | - | - |
| Net cash provided by financing activities | 710 | 1,264 | 3,110 | 851 |
| Effects of exchange rate changes on cash and cash equivalents | -10 | -18 | 5 | 25 |
| Net decrease in cash and cash equivalents | -693 | -205 | 651 | 49 |
| Cash and cash equivalents at the beginning of the period | 900 | 1,105 | 405 | - |
| Cash and cash equivalents at the end of the period | 207 | 900 | 1,105 | - |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)